The patient a 48-year-old male, underwent nephrectomy for clear cell renal cell carcinoma. After surgery, the patient was treated sequentially with sunitinib, axitinib, and everolimus for multiple pulmonary metastases and iliopsoas muscle metastasis.
To compare the detection rate of clinically significant cancer (CSCa) by magnetic resonance imaging-targeted biopsy (MRI-TB) with that by standard systematic biopsy (SB) and to evaluate the role of MRI-TB as a replacement from SB in men at clinical risk of prostate cancer.
The present research was performed to clarify the differences in circulating tumor cells (CTCs) counts between non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) bladder cancer following transurethral resection of bladder tumor (TURBT).
Fibroblast Growth Factors (FGFs) are a family of proteins possessing paracrine, autocrine or endocrine functions in a variety of biological processes, including embryonic development, angiogenesis, tissue homeostasis, wound repair, and cancer.
While chimeric antigen receptor (CAR) T cell immunotherapy targeting CD19 has shown remarkable success in patients with lymphoid malignancies, the potency of CAR T cells in solid tumors is low so far.
[18F]PSMA-1007, a positron emission tomography (PET) tracer, specifically targets prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer. PSMA-PET is effective especially for regional detection of biochemical recurrence, which significantly affects patient management.
The protocol for preparation of computed tomography urography (CTU) examinations at our hospital was changed in 2013 to improve the quality of urinary bladder filling in the excretory phase. The aim of this study was to evaluate the quality of urinary bladder filling on CTU after different doses of furosemide were administered to patients with […]
Due to the discomfort and incidence of complications increases with the increasing number of biopsy cores, the protocol of prostate biopsy has been promoted from systematic biopsy (SB) to targeted biopsy (TB) in many studies.
Alicia Morgans: Hi, my name is Alicia Morgans, GU medical oncologist and Associate Professor of Medicine at Northwestern in Chicago. I am so excited to have here with me today, Dr. Sumit Subudhi, who is an Assistant Professor of Medicine in the Department of GI Medical Oncology at MD Anderson. Thank you so much for being […]
Alicia Morgans: Hi, my name is Alicia Morgans, GU medical oncologist and associate professor of medicine at Northwestern University in Chicago. I am so excited to have here with me today, Dr. Stephen Freedland, who’s a professor of surgery and a urologist at Cedars-Sinai in Los Angeles, as well as being the editor in chief for […]
